IHH Healthcare registered a net profit of $573m (RM$1.9b) in year-to-date (YTD) 2024, dropping 13% year-on-year (YoY).
The decrease was due to a high base last year, which recorded one-off gains of $263m (RM873.0m) from the sale of International Medical University (IMU). Excluding exceptional items, net profit grew by 35%.
Revenue and EBITDA for the period posted double-digit growth of 13% and 12%, respectively, reaching $5.3b (RM17.7b) and $1.2b (RM4.0b). The growth was driven by sustained increases in patient volumes and revenue intensity across all markets.
For Q3 2024, IHH Healthcare achieved a 73% occupancy rate, with 232,071 patient admissions across 12,220 operational beds.
In the next five years, the group intends to add approximately 4,000 new beds under its “Align-Challenge-Empower” (ACE) framework.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。